There were significant improvements in all measured variables at the posttest compared to the baseline (P ≤ 0.05), whereas the measured variables remained unchanged in the control (CON) group (
Tables 2 and
3). The ANCOVA, after adjustments for pretest measurements as covariates, showed improvements in the mean of the measured variables in the intervention groups: Orexin-A (HIIT: 23.27 % vs. CON: -4.10%, P = 0.001; MIIT: 23.23% vs. CON: -4.10%, P = 0.001; HIIT: 23.27% vs. MIIT: 23.23%, P = 0.415), glucose (HIIT: -6.01 % vs. CON: -1.09%, P = 0.009; MIIT: -8.33% vs. CON: -1.09%, P = 0.001; HIIT: -6.01% vs. MIIT: -8.33%, p = 0.649), insulin (HIIT: -25.38 % vs. CON: -0.22%, P = 0.001; MIIT: -20.02% vs. CON: -0.22%, P = 0.006; HIIT: -25.38% vs. MIIT: -20.02%, P = 0.82), HOMA-IR (HIIT: -3.28 % vs. CON: -0.97%, P = 0.035; MIIT: -8.37% vs. CON: -0.97%, P = 0.002; HIIT: -3.28% vs. MIIT: -8.37%, P = 0.058), uric acid (HIIT: -8.58% vs. CON: 1.91%, P = 0.228; MIIT: -10.06% vs. CON: 1.91%, P = 0.011; HIIT: -8.58% vs. MIIT: -10.06%, P = 0.25), BMI (HIIT: -3.18% vs. CON: -0.49%, P = 0.001; MIIT: -3.22% vs. CON: -0.49%, P = 0.001; HIIT: -3.18% vs. MIIT: -3.22%, P = 0.77), and VO
2peak (HIIT: 14.83% vs. CON: 1.67%, P = 0.001; MIIT: 10.10% vs. CON: 1.67%, P = 0.001; HIIT: 14.83% vs. MIIT: 10.10%, P = 0.029). On the other hand, as shown in
Table 1, there were no significant differences in the WHR level (HIIT: -3.44 % vs. CON: -1.12%, P = 0.49; MIIT: -3.57% vs. CON: -1.12%, P = 0.46; HIIT: -3.44% vs. MIIT: -3.57%, P = 0.75) and %BF between the groups (HIIT: -7.23% vs. CON:-3.69%, P = 0.11; MIIT: -6.46% vs. CON: -3.69%, P = 0.11; HIIT: -7.23% vs. MIIT: -6.46%, P = 0.67).